Hepatitis B in Africa Collaborative Network (HEPSANET): multi-regional partnership to advance science and public health using local data,
Lien de l'article:
Auteur(s): Nicholas Riches,1 Michael Vinikoor,2 Alice Guingane,3 Asgeir Johannessen,4 Maud Lemoine,5 Philippa Matthews,6 Edith Okeke,7 Yusuke Shimakawa,8 Roger Sombie,9 Alexander Stockdale,10 Gilles Wandeler,11 Monique Andersson,12 Pantong Davwar,7 Hailemichael Desalegn,13 Mary Duguru,7 Fatou Fall,14 Tongai Maponga,15 David Nyam Paul,7 Moussa Seydi,16 Edford Sinkala,2 Jantjie Taljaard,17 Mark Sonderup,18 and C. Wendy Spearman,
Auteur(s) tagués: Arsène Roger SOMBIÉ ;
Résumé

Background:
To close knowledge gaps around hepatitis B virus (HBV) infection in Africa, a multi-country research collaboration was formed. Here we summarize the initial outputs of the collaboration and direction for the future.

Methods:
Following the 2020 COLDA, HEPSANET was established. Major groups implementing longitudinal HBV cohorts in Africa signed a data-sharing agreement and undertook an initial data sharing exercise that focused on baseline, cross-sectional, pre-treatment data from PLHBV. HEPSANET has now moved into harmonization of longitudinal data and added additional sites. A codebook was created to harmonize existing electronic or paper data at site level. A REDCap database (in French and English) was created for sites with paper data. All PLHBV who sought care at least once at the sites were included. A final cohort outcome (alive and retained, transferred, died, withdrew, or lost to follow-up [LTFU]), was assigned to each PLHBV. Phone and physical tracing were attempted for all LTFU. Sites using the REDCAP received additional mentorship through a series of data quality meetings.

Results:
At baseline, among 4,173 PLHBV analyzed (1118-East, 923-Southern, and 2132-West Africa), median age was 34 years, 38.9% were women, and 81.3% were diagnosed with HBV infection through targeted asymptomatic testing. 90.4% were HBeAg-negative and 14.3% had cirrhosis based on median liver stiffness =9.5 kPa. Approximately half of non-cirrhotic untreated PLHBV had an ‘indeterminate’ clinical phenotype (either elevated ALT with HBV DNA

Mots-clés

962
Enseignants
5577
Publications
49
Laboratoires
84
Projets